Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bolen, 2007, Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus, Ann Intern Med, 147, 386, 10.7326/0003-4819-147-6-200709180-00178
Bergenstal, Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications, 10.1016/j.amjmed.2009.07.017
Nyenwe, 2011, Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes, Metabolism, 60, 1, 10.1016/j.metabol.2010.09.010
Nolan, 2010, Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes, Diabetologia, 53, 1247, 10.1007/s00125-010-1767-z
Blonde, 2010, Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus, Am J Med, 123, S12, 10.1016/j.amjmed.2009.12.005
Greenfield, 2009, Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study, Ann Intern Med, 151, 854, 10.7326/0003-4819-151-12-200912150-00005
Matthews, 2008, Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes, Diab Vasc Dis Res, 5, 216, 10.3132/dvdr.2008.036
Skyler, 2009, Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association, Diabetes Care, 32, 187, 10.2337/dc08-9026
Yudkin, 2011, Intensified glucose control in type 2 diabetes—whose agenda?, Lancet, 377, 1220, 10.1016/S0140-6736(10)61112-9
Nathan, 2009, Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia, 52, 17, 10.1007/s00125-008-1157-y
IDF Clinical Guidelines Task Force, 2005, Global Guideline for Type 2 Diabetes
Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, Endocr Pract, 15, 540, 10.4158/EP.15.6.540
Berard, 2008, Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada, Canadian Journal of Diabetes, 32, S1
NICE, 2009, Type 2 Diabetes: The Management of Type 2 Diabetes: NICE Clinical Guideline 87
Home, 2008, Management of type 2 diabetes: summary of updated NICE guidance, BMJ, 336, 1306, 10.1136/bmj.39560.442095.AD
Davidson, 2010, Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, Mayo Clin Proc, 85, S27, 10.4065/mcp.2010.0469
DeFronzo, 2010, Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going, Am J Med, 123, S38, 10.1016/j.amjmed.2009.12.008
Murad, 2011, Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences, J Clin Epidemiol, 64, 743, 10.1016/j.jclinepi.2010.08.005
Glasgow, 2008, Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures, Diabetes Care, 31, 1046, 10.2337/dc07-1845
Ismail-Beigi, 2011, Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials, Ann Intern Med, 154, 554, 10.7326/0003-4819-154-8-201104190-00007
Mullan, 2009, The diabetes mellitus medication choice decision aid: a randomized trial, Arch Intern Med, 169, 1560, 10.1001/archinternmed.2009.293
Schernthaner, 2010, Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis, Diabetologia, 53, 1258, 10.1007/s00125-010-1702-3
Gandhi, 2008, Patient-important outcomes in registered diabetes trials, JAMA, 299, 2543, 10.1001/jama.299.21.2543
Smith, 2010, Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know, J Clin Endocrinol Metab, 95, 1566, 10.1210/jc.2009-1966
Committee on Quality of Health Care in America, 2001, Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century
Guyatt, 2000, Users’ Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users’ Guides to patient care, JAMA, 284, 1290, 10.1001/jama.284.10.1290
Tsapas, 2008, N of 1 trials in diabetes: making individual therapeutic decisions, Diabetologia, 51, 921, 10.1007/s00125-008-0983-2
Shah, 2010, Translating comparative effectiveness into practice: the case of diabetes medications, Med Care, 48, S153, 10.1097/MLR.0b013e3181d5956c
Stratton, 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, 321, 405, 10.1136/bmj.321.7258.405
Turner, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6
UKPDS Group, 1991, UK Prospective Diabetes Study VIII: study design, progress and performance, Diabetologia, 34, 877, 10.1007/BF00400195
Turner, 1998, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8
Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med, 359, 1577, 10.1056/NEJMoa0806470
Gerstein, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743
Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med, 358, 2560, 10.1056/NEJMoa0802987
Turnbull
Ferrannini, 2005, Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis, J Clin Endocrinol Metab, 90, 493, 10.1210/jc.2004-1133
Nauck, 2011, Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications, Am J Med, 124, S3, 10.1016/j.amjmed.2010.11.002
Ferrannini, 2010, The stunned beta cell: a brief history, Cell Metab, 11, 349, 10.1016/j.cmet.2010.04.009
Nauck, 2009, Unraveling the science of incretin biology, Am J Med, 122, S3, 10.1016/j.amjmed.2009.03.012
Groop, 1993, Insulin action and substrate competition, Baillieres Clin Endocrinol Metab, 7, 1007, 10.1016/S0950-351X(05)80243-5
American Diabetes Association, 2011, Standards of medical care in diabetes—2011, Diabetes Care, 34, S11, 10.2337/dc11-S011
Akalin, 2009, Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control, Int J Clin Pract, 63, 1421, 10.1111/j.1742-1241.2009.02165.x
Lee, 2011, Goals of glycemic control in frail older patients with diabetes, JAMA, 305, 1350, 10.1001/jama.2011.404
Ahmed, 2009, Current treatment of non-alcoholic fatty liver disease, Diabetes Obes Metab, 11, 188, 10.1111/j.1463-1326.2008.00926.x
Anderson, 2003, Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies, J Am Coll Nutr, 22, 331, 10.1080/07315724.2003.10719316
Klein, 2004, Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition, Diabetes Care, 27, 2067, 10.2337/diacare.27.8.2067
Bantle, 2008, Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association, Diabetes Care, 31, S61
Elmer, 2006, Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial, Ann Intern Med, 144, 485, 10.7326/0003-4819-144-7-200604040-00007
Gordon, 2004, Effectiveness of therapeutic lifestyle changes in patients with hypertension, hyperlipidemia, and/or hyperglycemia, Am J Cardiol, 94, 1558, 10.1016/j.amjcard.2004.08.039
Wing, 2006, A self-regulation program for maintenance of weight loss, N Engl J Med, 355, 1563, 10.1056/NEJMoa061883
Boulé, 2001, Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials, JAMA, 286, 1218, 10.1001/jama.286.10.1218
Lamanna, 2011, Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials, Diabetes Obes Metab, 13, 221, 10.1111/j.1463-1326.2010.01349.x
Bryan, 2005, Insulin secretagogues, sulfonylurea receptors and K(ATP) channels, Curr Pharm Des, 11, 2699, 10.2174/1381612054546879
Kahn, 2006, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, N Engl J Med, 355, 2427, 10.1056/NEJMoa066224
Gerich, 2005, PRESERVE-β: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin, Diabetes Care, 28, 2093, 10.2337/diacare.28.9.2093
Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9
Nissen, 2010, Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality, Arch Intern Med, 170, 1191, 10.1001/archinternmed.2010.207
Lewis, 2011, Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study, Diabetes Care, 34, 916, 10.2337/dc10-1068
Drucker, 2006, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet, 368, 1696, 10.1016/S0140-6736(06)69705-5
Deacon, 2011, Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review, Diabetes Obes Metab, 13, 7, 10.1111/j.1463-1326.2010.01306.x
Van de Laar, 2006, Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose, Cochrane Database Syst Rev, 10.1002/14651858.CD005061.pub2
Fonseca, 2010, Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence, Diabetes Obes Metab, 12, 384, 10.1111/j.1463-1326.2009.01181.x
DeFronzo, 2011, Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes, Diabetes Care, 34, 789, 10.2337/dc11-0064
Singh-Franco, 2007, Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus, Clin Ther, 29, 535, 10.1016/j.clinthera.2007.04.005
Peters, 2010, Incretin-based therapies: review of current clinical trial data, Am J Med, 123, S28, 10.1016/j.amjmed.2009.12.007
Bennett, 2011, Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations, Ann Intern Med, 154, 602, 10.7326/0003-4819-154-9-201105030-00336
Jabbour, 2008, Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both?, Int J Clin Pract, 62, 845, 10.1111/j.1742-1241.2008.01757.x
Bergenstal, 2008, Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine, Diabetes Care, 31, 1305, 10.2337/dc07-2137
Cryer, 2002, Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes, Diabetologia, 45, 937, 10.1007/s00125-002-0822-9
Holman, 2009, Three-year efficacy of complex insulin regimens in type 2 diabetes, N Engl J Med, 361, 1736, 10.1056/NEJMoa0905479
Hermansen, 2006, A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes, Diabetes Care, 29, 1269, 10.2337/dc05-1365
Riddle, 2006, The Treat-to-Target Trial and related studies, Endocr Pract, 12, 71, 10.4158/EP.12.S1.71
Rosenstock, 2008, A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes, Diabetologia, 51, 408, 10.1007/s00125-007-0911-x
Simonson, 2011, International Diabetes Center treatment of type 2 diabetes glucose algorithm, Diabetes Management, 1, 175, 10.2217/dmt.10.22
Gross, 2011, Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis, Ann Intern Med, 154, 672, 10.7326/0003-4819-154-10-201105170-00007
Karagiannis, 2012, Dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis, BMJ, 344, e1369, 10.1136/bmj.e1369
Cryer, 2007, Severe iatrogenic hypoglycemia in type 2 diabetes mellitus, Nat Clin Pract Endocrinol Metab, 3, 4, 10.1038/ncpendmet0355
Loke, 2011, Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies, BMJ, 342, d1309, 10.1136/bmj.d1309
Kendall, 2005, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea, Diabetes Care, 28, 1083, 10.2337/diacare.28.5.1083
Zinman, 2009, Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD), Diabetes Care, 32, 1224, 10.2337/dc08-2124
Roberts, 2005, Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study, Clin Ther, 27, 1535, 10.1016/j.clinthera.2005.10.017
Bell, 2011, Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II), Diabetes Obes Metab, 13, 800, 10.1111/j.1463-1326.2011.01408.x
Rosenstock, 2006, Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients, Diabetes Care, 29, 554, 10.2337/diacare.29.03.06.dc05-0695
Yki-Järvinen, 2007, Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups, Diabetes Care, 30, 1364, 10.2337/dc06-1357
Davies, 2005, Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine, Diabetes Care, 28, 1282, 10.2337/diacare.28.6.1282
Garber, 2009, The importance of titrating starting insulin regimens in patients with type 2 diabetes, Diabetes Obes Metab, 11, 10, 10.1111/j.1463-1326.2009.01138.x
Owens, 2011, Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study, Diabetes Obes Metab, 13, 1020, 10.1111/j.1463-1326.2011.01459.x
Davidson, 2011, A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure, Endocr Pract, 17, 395, 10.4158/EP10323.OR
Raccah, 2008, Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus, Diabetes Obes Metab, 10, 76, 10.1111/j.1463-1326.2008.00846.x
Ilag, 2007, Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison, Clin Ther, 29, 1254, 10.1016/j.clinthera.2007.07.003
Avilés-Santa, 1999, Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 131, 182, 10.7326/0003-4819-131-3-199908030-00004
Strowig, 2005, Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus, Diabetes Obes Metab, 7, 633, 10.1111/j.1463-1326.2004.00440.x
Buse, 2011, Type 2 diabetes mellitus in 2010: individualizing treatment targets in diabetes care, Nat Rev Endocrinol, 7, 67, 10.1038/nrendo.2010.230
Vilsbøll, 2010, Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes, Diabetes Obes Metab, 12, 167, 10.1111/j.1463-1326.2009.01173.x
Del Prato, 2003, Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis, Diabetes Care, 26, 2075, 10.2337/diacare.26.7.2075
Booth, 2006, Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study, Lancet, 368, 29, 10.1016/S0140-6736(06)68967-8
Nelson, 2007, The relationship between glycemic control and falls in older adults, J Am Geriatr Soc, 55, 2041, 10.1111/j.1532-5415.2007.01430.x
Sluik, 2011, Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus, Am J Epidemiol, 174, 22, 10.1093/aje/kwr048
Unick, 2011, Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial, Diabetes Care, 34, 2152, 10.2337/dc11-0874
Krentz, 2005, Oral antidiabetic agents: current role in type 2 diabetes mellitus, Drugs, 65, 385, 10.2165/00003495-200565030-00005
Buchwald, Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis, 10.1016/j.amjmed.2008.09.041
Davis, 2005, Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70), Diabetologia, 48, 695, 10.1007/s00125-005-1690-x
Park, 2003, The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994, Arch Intern Med, 163, 427, 10.1001/archinte.163.4.427
Chen, 1995, Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men, Diabetes Care, 18, 747, 10.2337/diacare.18.6.747
Kahn, 2003, The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes, Diabetologia, 46, 3, 10.1007/s00125-002-1009-0
Malecki, 2008, Monogenic diabetes: implications for therapy of rare types of disease, Diabetes Obes Metab, 10, 607, 10.1111/j.1463-1326.2007.00736.x
Nordin, 2010, The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence, Diabetologia, 53, 1552, 10.1007/s00125-010-1752-6
Riveline, 2003, Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications, Diabetes Metab, 29, 207, 10.1016/S1262-3636(07)70030-7
Sulistio, 2009, GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects, Curr Atheroscler Rep, 11, 93, 10.1007/s11883-009-0015-9
Hanefeld, 2008, Acarbose: oral anti-diabetes drug with additional cardiovascular benefits, Expert Rev Cardiovasc Ther, 6, 153, 10.1586/14779072.6.2.153
Gaziano, 2010, Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes, Diabetes Care, 33, 1503, 10.2337/dc09-2009
Masoudi, 2007, Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy, Am J Cardiol, 99, 113B, 10.1016/j.amjcard.2006.11.013
Lago, 2007, Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials, Lancet, 370, 1129, 10.1016/S0140-6736(07)61514-1
Chaggar, 2009, Review article: Thiazolidinediones and heart failure, Diab Vasc Dis Res, 6, 146, 10.1177/1479164109338772
Tahrani, 2007, Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?, BMJ, 335, 508, 10.1136/bmj.39255.669444.AE
Inzucchi, 2008, New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond, Circulation, 117, 574, 10.1161/CIRCULATIONAHA.107.735795
Huang, 2011, Glycemic control, complications, and death in older diabetic patients: the Diabetes and Aging Study, Diabetes Care, 34, 1329, 10.2337/dc10-2377
Koro, 2009, Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States, Clin Ther, 31, 2608, 10.1016/j.clinthera.2009.10.020
Holstein, 2005, Contraindications can damage your health—is metformin a case in point?, Diabetologia, 48, 2454, 10.1007/s00125-005-0026-1
Lipska, 2011, Use of metformin in the setting of mild-to-moderate renal insufficiency, Diabetes Care, 34, 1431, 10.2337/dc10-2361
Nye, 2011, Metformin: the safest hypoglycaemic agent in chronic kidney disease?, Nephron Clin Pract, 118, c380, 10.1159/000323739
Ong, 2007, Epidemiology and natural history of NAFLD and NASH, Clin Liver Dis, 11, 1, 10.1016/j.cld.2007.02.009
Musso, 2011, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, Ann Med, 43, 617, 10.3109/07853890.2010.518623
Tushuizen, 2006, Incretin mimetics as a novel therapeutic option for hepatic steatosis, Liver Int, 26, 1015, 10.1111/j.1478-3231.2006.01315.x
Gerstein, 2011, Long-term effects of intensive glucose lowering on cardiovascular outcomes, N Engl J Med, 364, 818, 10.1056/NEJMoa1006524
Bonds, 2010, The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study, BMJ, 340, b4909, 10.1136/bmj.b4909
Riddle, 2010, Counterpoint: Intensive glucose control and mortality in ACCORD—still looking for clues, Diabetes Care, 33, 2722, 10.2337/dc10-1658
Berlie, 2010, Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly, Ann Pharmacother, 44, 712, 10.1345/aph.1M551
Rodbard, 2010, The combinatorics of medications precludes evidence-based algorithms for therapy, Diabetologia, 53, 2456, 10.1007/s00125-010-1904-8